Fig. 1
From: A validation study of crescents in predicting ESRD in patients with IgA nephropathy
Kaplan–Meier curves of the cumulative risk of the primary outcome for patients in each crescent group: all patients (a), those with immunosuppression (b), and those without immunosuppression (c). Kaplan-Meier curves of the cumulative risk of the secondary outcome for patients in each crescent group: all patients (d), those with immunosuppression (e), and those without immunosuppression (f). The mean primary outcome-free survival times for the C0, C1, C2, and C1 + C2 groups were 176.3 ± 7.5, 225.4 ± 14.8, 168.9 ± 7.3 and 187.5 ± 18.6 months (PC1 vs C0 = 0.45, PC2 vs C0 = 0.37, PC1+C2 vs C0 = 0.82) for all patients; 146.3 ± 13.4, 132.6 ± 6.2, 134.2 ± 11.8 and 139.4 ± 8.4 (PC1 vs C0, = 0.27, PC2 vs C0 = 0.77, PC1+C2 vs C0 = 0.39) for patients with immunosuppression; and 190.4 ± 9.6, 225.1 ± 23.0, 151.9 ± 23.5 and 188.1 ± 25.4 months (PC1 vs C0 = 0.66, PC2 vs C0 = 0.59, PC1+C2 vs C0 = 0.87) for patients without immunosuppression, respectively. The mean secondary outcome-free survival times for the C0, C1, C2, and C1 + C2 groups were 163.7 ± 7.8, 188.9 ± 18.3, 140.9 ± 11.1 and 171.7 ± 16.3 months (PC1 vs C0 = 0.73, PC2 vs C0 = 0.52, PC1+C2 vs C0 = 0.98) for all patients; 138.6 ± 14.0, 117.0 ± 8.1, 131.8 ± 11.7 and 130.0 ± 8.1 months (PC1 vs C0, = 0.60, PC2 vs C0 = 0.93, PC1+C2 vs C0 = 0.67) for patients with immunosuppression; and 171.9 ± 10.2, 197.8 ± 25.6, 151.9 ± 23.5 and 172.7 ± 22.1 months (PC1 vs C0 = 0.81, PC2 vs C0 = 0.94, PC1+C2 vs C0 = 0.89) for patients without immunosuppression, respectively